Saturday 17 October 2026
Export DSGN’s income statement to Excel — free account
Design Therapeutics, Inc.
DSGN Healthcare Biotechnology
In the quarter to June 2026, EPS grew 5.88% and free cash flow fell 7.00%, each against the same quarter a year earlier.
10.31
0.17
−1.62%
Follow DSGN
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
— | — | — | — |
+8 more quarters Free account |
EV/Sales |
— | — | — | — | |
EV/FCF |
— | — | — | — | |
Quick Ratio |
18.45 | 21.87 | 16.84 | 18.43 | |
Current Ratio |
18.86 | 22.28 | 17.14 | 18.71 | |
Net Debt/EBITDA |
9.41 | 11.31 | 11.87 | 10.34 | |
Debt/Assets |
0.00% | 0.00% | 0.00% | 0.00% | |
Debt/Equity |
0.00 | 0.00 | 0.00 | 0.00 | |
Asset Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF/Net income |
0.77 | 0.93 | 0.75 | 0.66 | |
Capex/Depreciation |
(0.15) | 0.00 | 0.10 | 0.00 | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Free Cash Flow Yield |
— | — | — | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(0.25) | (0.27) | (0.21) | (0.20) | |
Capex per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Free Cash Flow per Share |
(0.25) | (0.27) | (0.21) | (0.20) | |
Cash per Share |
3.32 | 3.63 | 3.83 | 3.62 | |
Shareholders Equity per Share |
3.23 | 3.55 | 3.71 | 3.51 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
3.23 | 3.55 | 3.71 | 3.51 | |
Free Cash Flow |
(15.54) | (16.43) | (12.00) | (11.16) | |
Working Capital |
200.77 | 216.86 | 210.73 | 197.86 | |
Capital Expenditures |
(0.02) | — | (0.03) | 0.00 | |
Net Current Asset Value |
198.74 | 214.66 | 210.08 | 196.98 | |
EV/EBIT |
— | — | — | — | |
Capex to Sales |
0.00 | — | 0.00 | 0.00 | |
| Other line items | |||||
Average Payables |
2.08 | 2.73 | 2.25 | 1.69 | |
Average Assets |
219.01 | 233.96 | 239.15 | 236.70 | |
Average Common Equity |
207.45 | 222.99 | 227.30 | 226.09 |
Columns are period end dates